It is the responsibility of the investigator to ensure that the IP is only dispensed to study participants. The IP must be dispensed only from official study sites by authorized personnel according to local regulations. Revised Protocol No.: 04 Date: 31-May-2019 90 Approved 5.0 v Approved 1.0 v Clinical Protocol CA021002 BMS-986226 anti-ICOS The product storage manager should ensure that the study treatment is stored in accordance with the environmental conditions (temperature, lig ht, and humidity) as determined by BMS. If concerns regarding the quality or appearance of the study tr eatment arise, the st udy tr eatment should not be dispense d and contact BMS immediately.